Abbott Laboratories (ABT) Accounts Payables (2009 - 2026)

Abbott Laboratories has disclosed Accounts Payables across 18 years of filings, most recently posting $4.8 billion for Q2 2026.

• In Q2 2026, Accounts Payables rose 11.33% year-over-year to $4.8 billion; the TTM figure through Jun 2026 stood at $4.8 billion (up 11.33% YoY), while the FY2025 annual figure was $4.2 billion, up 1.07% from the prior year.
• Accounts Payables came in at $4.8 billion for Q2 2026 at Abbott Laboratories, up from $4.7 billion in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.8 billion in Q2 2026 to a low of $4.0 billion in Q3 2023.
• Average Accounts Payables over 5 years is $4.3 billion, with a median of $4.2 billion recorded in 2023.
• Year-over-year, Accounts Payables gained 16.99% in 2022 and decreased 12.4% in 2023.
• Over 5 years, Accounts Payables stood at $4.6 billion in 2022, then slipped by 6.77% to $4.3 billion in 2023, then decreased by 2.33% to $4.2 billion in 2024, then climbed by 1.07% to $4.2 billion in 2025, then climbed by 13.07% to $4.8 billion in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $4.8 billion in Q2 2026, $4.7 billion in Q1 2026, and $4.2 billion in Q4 2025.